TY  - JOUR

T1  - Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study

JO  - Journal of Allergy and Clinical Immunology

PY  - 2021/02/01

AU  - McMichael A

AU  - Cork M

AU  - Teng J

AU  - Rojo R

AU  - Valdez H

AU  - Zhang F

AU  - Myers D

AU  - Chan G

AU  - DiBonaventura M

ED  - 

DO  - DOI: 10.1016/j.jaci.2020.12.560

VL  - 147

IS  - 2

SP  - ab156

Y2  - 2024/12/22

ER  -